Compare IMRN & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMRN | INBS |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.4M |
| IPO Year | 2016 | 2019 |
| Metric | IMRN | INBS |
|---|---|---|
| Price | $0.79 | $3.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.4K | ★ 78.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.54 |
| 52 Week High | $2.38 | $24.90 |
| Indicator | IMRN | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 32.99 |
| Support Level | $0.69 | $1.49 |
| Resistance Level | $1.96 | $7.25 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 22.79 | 8.33 |
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.